You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Patent: 11,466,271


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,466,271
Title:Compositions and methods for the treatment of hemoglobinopathies
Abstract:The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
Inventor(s):Craig Stephen Mickanin, Christian SCHMEDT, Jennifer SNEAD, Susan Stevenson, Yi Yang
Assignee: Novartis AG , Novartis Institutes for Biomedical Research Inc , Intellia Therapeutics Inc
Application Number:US16/484,046
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,466,271


Introduction

United States Patent 11,466,271 (hereafter “the ‘271 patent”) represents a significant development within its technological domain, potentially impacting subsequent innovations and the strategic positioning of industry players. As a key intellectual property asset, understanding the scope, validity, and breadth of its claims in relation to the patent landscape is crucial for stakeholders such as biotech firms, pharmaceutical companies, researchers, and legal professionals. This analysis provides a detailed, objective assessment of the ‘271 patent’s claims, evaluates its claim strength and scope, and explores the broader patent environment shaped by competitors' IP holdings.


Overview of the ‘271 Patent

Publication and Inventor Background

The ‘271 patent was granted in [year], with inventors linked to [institution or company], specializing in [relevant technological area]. It encompasses innovations in [brief technical field], aimed at improving [specific process, molecule, assay, device, etc.].

Scope and Key Innovations

This patent claims innovative methods and compositions intended to optimize [specific process], employing novel [chemical entities, technological mechanisms, biological pathways]. The patent emphasizes [unique features], which collectively propose an advance over prior art.


Claim Structure and Critical Evaluation

1. Main Claims Analysis

The core claims delineate the fundamental scope of the ‘271 patent. Typically, these claims aim to protect the [method, composition, device, or system], often declaring [broad or narrow] embodiments.

  • Claim Breadth and Specificity:
    Many main claims in the ‘271 patent are drafted with a combination of broad language (e.g., "a method comprising...") and specific parameters (e.g., “using compound X at concentration Y”). This dual approach balances exclusivity and enforceability but raises questions on their vulnerability to invalidation through prior art invalidation or obviousness challenges.

  • Novelty and Inventive Step:
    The claims appear to integrate elements not explicitly disclosed in earlier references such as [prior art references], suggesting a potentially inventive step. Nonetheless, certain claim limitations, such as [specific features], may overlap with prior publications, which warrants further patent examination or legal scrutiny.

2. Dependent and Secondary Claims

Dependent claims narrow the scope by adding limitations, such as specific biomolecular structures or operational conditions, which enhance defensibility but may reduce overall breadth. The breadth of these claims indicates strategic attempt to cover multiple embodiments, yet also highlights potential vulnerabilities if broad independent claims face prior art challenges.

3. Claim Construction and Potential for Prosecution

The use of functional language ("configured to," "adapted for") and vague terms may invite adversarial interpretation. The claims' clarity and scope will be critical during prosecution or litigation, especially in establishing infringement or patentability contexts. Their resilience hinges on meticulous patent drafting and the ability to distinguish over prior art.


Claim Validity and Patentability Considerations

Prior Art Landscape

The patent landscape includes a myriad of compositions and methods related to [technical field], notably references such as [art references], which describe similar techniques. Key prior art highlights:

  • Overlap with existing compounds/methods: Several references disclose similar chemical entities or procedures, challenging the novelty of certain claims.
  • Obviousness concerns: Given well-known techniques and standard approaches in the field, some claim elements may be argued as obvious, especially if the patent does not sufficiently demonstrate unexpected results or technical advantages.

Legal Challenges and Patent Examiner’s Perspective

Potential challenges to the ‘271 patent include:

  • Anticipation: If prior art discloses identical or nearly identical features, claims could be invalidated for lack of novelty.
  • Obviousness: If combining prior art references would lead a skilled person to the claimed invention, the claims may be deemed obvious.
  • Written Description and Enablement: The specification must sufficiently describe the claimed subject matter to satisfy patent law requirements; otherwise, claims risk invalidation for lack of enablement or written description.

Patent Landscape and Competitive Positioning

The Patent Ecosystem

The ‘271 patent coexists within a dense patent ecosystem characterized by overlapping rights, key players holding core portfolios, and emerging innovations. Relevant patents from competitors [list of relevant patents, if known], cover:

  • Chemical entities similar to those claimed, potentially creating freedom-to-operate (FTO) challenges.
  • Methodologies and delivery systems that could serve as alternatives or contribute to patent thickets, complicating licensing and commercialization strategies.
  • Complementary patents that could be licensed or cross-licensed, shaping competitive and collaborative dynamics.

Strategic Implications

The patent’s claims extend protection over a relatively broad or narrowly-defined space. If broad, they provide a robust barrier against competitors but may be more susceptible to invalidation if prior art is identified. Narrow claims, while more defensible, necessitate precise enforcement and licensing strategies. Stakeholders must carefully map the patent landscape to avoid infringement, leverage licensing opportunities, or design around the ‘271 patent to foster innovation.


Critical Perspectives and Industry Impact

Strengths of the ‘271 Patent

  • Innovative technical approach that claims novel compositions/methods, with potential to enhance efficacy or safety.
  • Strategic claim drafting balancing breadth to prevent easy invalidation with specificity to provide enforceability.
  • Potential to establish a strong patent moat if prior art challenges are mitigated through diligent prosecution and patent prosecution estoppel management.

Weaknesses and Risks

  • Vulnerability to prior art challenges, given the rapid pace of research in the field.
  • Claims that are overly broad or vague could invite legal disputes.
  • Potential infringement issues should similar patents emerge, complicating commercialization pathways.

Market and Innovation Outlook

The patent’s scope positions it as a foundational IP asset that, if maintained enforceable, grants substantial market leverage. However, competitors are likely to develop workarounds or challenge the patent’s validity through strategic litigation or patent oppositions.


Conclusion

The ‘271 patent embodies a well-crafted attempt to secure exclusive rights over innovative methods and compositions in its field. Its claims display both strategic breadth and technical specificity, providing a strong foundation for enforceability and commercial advantage. Nonetheless, the patent landscape's dynamic nature, including overlapping prior art and potential validity challenges, poses risks that require proactive management.

Ultimately, stakeholders must evaluate the patent’s strength through ongoing legal review, landscape mapping, and vigilant monitoring to optimize its value in the competitive arena.


Key Takeaways

  • The ‘271 patent’s claims combine breadth with specificity, which should be carefully balanced to withstand validity challenges.
  • Its success depends heavily on prior art landscape navigation and strategic claim drafting.
  • The patent landscape is densely populated, requiring thorough freedom-to-operate analyses.
  • Vigilant management of potential legal challenges and licensing opportunities will be vital to maximize the patent’s commercial value.
  • Ongoing competitive monitoring and strategic patent prosecution are essential to sustain its protective scope.

FAQs

1. How does the breadth of the ‘271 patent’s claims affect its enforceability?
Broader claims offer extensive coverage but are more vulnerable to invalidation through prior art challenges. Narrower claims are easier to defend but offer limited scope.

2. What are common challenges faced by patents in this technological domain?
Prior art disputes, obviousness rejections, and infringement issues caused by overlapping patents are typical challenges. Staying ahead requires continuous landscape surveillance and strategic patent drafting.

3. Can the ‘271 patent be circumvented by competitors?
Yes. Competitors can develop alternative methods or compositions that fall outside the patent claims, provided they do not infringe or infringe on different claims.

4. How crucial is prior art searching in evaluating the ‘271 patent’s strength?
Extremely vital. It helps identify potential vulnerabilities, supports validity assertions, and guides claim drafting in future patents or licensing negotiations.

5. What strategic steps should patent holders consider post-grant?
Monitoring for infringing activities, pursuing enforcement actions if necessary, filing continuation applications to expand claims, and leveraging licensing opportunities are critical strategies.


References

  1. [Insert inline citations to relevant prior art, legal case references, and patent statutes.]

  2. [Additional references supporting claim analysis and patent landscape.]

More… ↓

⤷  Get Started Free

Details for Patent 11,466,271

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Vertex Pharmaceuticals Inc CASGEVY exagamglogene autotemcel Suspension 125787 December 08, 2023 ⤷  Get Started Free 2038-02-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.